CD163 and melanoma: Blocking PD1/PD‐L1 signaling in CD163+ TAMs with antibodies could induce M1‐like polarization and increase macrophage phagocytosis, reduce tumor burden and prolong survival,14, 15 and result in an increased release of sCD163 in the lesional skin of melanoma.13